Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001233971 | SCV001406592 | uncertain significance | Kostmann syndrome | 2024-02-17 | criteria provided, single submitter | clinical testing | This sequence change replaces histidine, which is basic and polar, with glutamine, which is neutral and polar, at codon 56 of the HAX1 protein (p.His56Gln). This variant is present in population databases (rs756371972, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with HAX1-related conditions. ClinVar contains an entry for this variant (Variation ID: 960445). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004978168 | SCV005596129 | uncertain significance | Inborn genetic diseases | 2024-10-02 | criteria provided, single submitter | clinical testing | The p.H56Q variant (also known as c.168C>A), located in coding exon 2 of the HAX1 gene, results from a C to A substitution at nucleotide position 168. The histidine at codon 56 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |
Natera, |
RCV001233971 | SCV002085821 | uncertain significance | Kostmann syndrome | 2020-08-18 | no assertion criteria provided | clinical testing |